The ability of EGCG to bind the tyrosine domain of EGFR inhibiting its activation is widely known [60], as is the fact that 60–80% of cases of sporadic colorectal cancer (CRC) are associated with EGFR expression [61]. Here, EGFR is linked to colorectal carcinoma.